GAZYVA® – NCCN GUIDELINES® CATEGORY 1 DESIGNATION

• May 17, 2015
• Drugs

GAZYVA® – NCCN GUIDELINES® CATEGORY 1 DESIGNATION

Obinutuzumab (GAZYVA®) + chlorambucil is included in the NCCN Guidelines® with a category 1 designation for first-line therapy in the following CLL patients without del(17p)*:

– Age ≥70 years

– Younger patients (age <70 years) with significant comorbidities

– Frail patients with significant comorbidities

Note: Category 1 designation is given based upon high-level evidence and uniform NCCN consensus that the intervention is appropriate.

For full definitions of the NCCN Categories of Evidence and Consensus, please refer to the NCCN Guidelines, available online at www.nccn.org.